{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:05:00Z","timestamp":1764259500145},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T00:00:00Z","timestamp":1098748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1038\/sj.bjc.6602208","type":"journal-article","created":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T09:21:50Z","timestamp":1098782510000},"page":"1769-1774","source":"Crossref","is-referenced-by-count":117,"title":["Phase II study of S-1 in patients with advanced biliary tract cancer"],"prefix":"10.1038","volume":"91","author":[{"given":"H","family":"Ueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,10,26]]},"reference":[{"key":"BF6602208_CR1","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0959-8049(03)00237-5","volume":"39","author":"P Chollet","year":"2003","unstructured":"Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264\u20131270","journal-title":"Eur J Cancer"},{"key":"BF6602208_CR2","first-page":"2116","volume":"8","author":"SJ Cohen","year":"2002","unstructured":"Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ (2002) Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 8: 2116\u20132122","journal-title":"Clin Cancer Res"},{"key":"BF6602208_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/A:1026142601822","volume":"30","author":"E Comets","year":"2003","unstructured":"Comets E, Ikeda K, Hoff P, Fumoleau P, Wanders J, Tanigawara Y (2003) Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 30: 257\u2013283","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"BF6602208_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008241008379","volume":"9","author":"M Ducreux","year":"1998","unstructured":"Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9: 653\u2013656","journal-title":"Ann Oncol"},{"key":"BF6602208_CR5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1023\/A:1012543223020","volume":"12","author":"JO Gallardo","year":"2001","unstructured":"Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12: 1403\u20131406","journal-title":"Ann Oncol"},{"key":"BF6602208_CR6","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","volume":"19","author":"V Gebbia","year":"2001","unstructured":"Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M (2001) Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19: 4089\u20134091","journal-title":"J Clin Oncol"},{"key":"BF6602208_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0959-8049(97)10166-6","volume":"34","author":"M Hejna","year":"1998","unstructured":"Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34: 977\u2013986","journal-title":"Eur J Cancer"},{"key":"BF6602208_CR8","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000\u20132005","journal-title":"Clin Cancer Res"},{"key":"BF6602208_CR9","first-page":"1381","volume":"28","author":"Y Inuyama","year":"2001","unstructured":"Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381\u20131390","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF6602208_CR10","first-page":"101","volume":"28","author":"Japan Society for Cancer Therapy","year":"1993","unstructured":"Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101\u2013130","journal-title":"J Jpn Soc Cancer Ther"},{"key":"BF6602208_CR11","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.1996.14.8.2306","volume":"14","author":"DV Jones Jr","year":"1996","unstructured":"Jones Jr DV, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14: 2306\u20132310","journal-title":"J Clin Oncol"},{"key":"BF6602208_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1054\/bjoc.2001.2031","volume":"85","author":"M Kawahara","year":"2001","unstructured":"Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939\u2013943","journal-title":"Br J Cancer"},{"key":"BF6602208_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000012099","volume":"58","author":"W Koizumi","year":"2000","unstructured":"Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191\u2013197","journal-title":"Oncology"},{"key":"BF6602208_CR14","first-page":"783","volume":"48","author":"S Kubicka","year":"2001","unstructured":"Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M (2001) Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48: 783\u2013789","journal-title":"Hepatogastroenterology"},{"key":"BF6602208_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0378-4347(96)00429-X","volume":"691","author":"E Matsushima","year":"1997","unstructured":"Matsushima E, Yoshida K, Kitamura R (1997) Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 691: 95\u2013104","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BF6602208_CR16","first-page":"232","volume":"21","author":"J Mezger","year":"1998","unstructured":"Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C, Glasmacher A (1998) Phase II study of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 21: 232\u2013234","journal-title":"Onkologie"},{"key":"BF6602208_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141\u2013145","journal-title":"Br J Cancer"},{"key":"BF6602208_CR18","first-page":"656","volume":"20","author":"A Ohtsu","year":"2001","unstructured":"Ohtsu A, Boku N, Nagashima F, Koizumi W, Tanabe S, Saigenji K, Muro K, Matsumura Y, Shirao K (2001) A phase I\/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 20: 656","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602208_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000227396","volume":"51","author":"S Okada","year":"1994","unstructured":"Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51: 515\u2013517","journal-title":"Oncology"},{"key":"BF6602208_CR20","first-page":"171a","volume":"22","author":"S Okada","year":"2002","unstructured":"Okada S, Okusaka T, Ueno H, Ikeda M, Kuriyama H, Saisho T, Morizane C (2002) A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 22: 171a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602208_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/sonc.2002.37377","volume":"29","author":"T Okusaka","year":"2002","unstructured":"Okusaka T (2002) Chemotherapy for biliary tract cancer in Japan. Semin Oncol 29: 51\u201353","journal-title":"Semin Oncol"},{"key":"BF6602208_CR22","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0959-8049(01)00214-3","volume":"37","author":"P Papakostas","year":"2001","unstructured":"Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Georgoulias V (2001) First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 37: 1833\u20131838","journal-title":"Eur J Cancer"},{"key":"BF6602208_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00000421-199902000-00019","volume":"22","author":"R Pazdur","year":"1999","unstructured":"Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM, Burris HA (1999) Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22: 78\u201381","journal-title":"Am J Clin Oncol"},{"key":"BF6602208_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1008352123009","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12: 183\u2013186","journal-title":"Ann Oncol"},{"key":"BF6602208_CR25","first-page":"644","volume":"7","author":"A Polyzos","year":"1996","unstructured":"Polyzos A, Nikou G, Giannopoulos A, Toskas A, Kalahanis N, Papargyriou J, Michail P, Papachristodoulou A (1996) Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study. Ann Oncol 7: 644\u2013645","journal-title":"A phase II study. Ann Oncol"},{"key":"BF6602208_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000011961","volume":"56","author":"M Raderer","year":"1999","unstructured":"Raderer M, Hejna MH, Valencak J B, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W (1999) Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177\u2013180","journal-title":"Oncology"},{"key":"BF6602208_CR27","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1\u2009M tegafur\u20130.4\u2009M gimestat\u20131\u2009M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715\u20131720","journal-title":"Eur J Cancer"},{"key":"BF6602208_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1023\/A:1011135014895","volume":"12","author":"PM Sanz-Altamira","year":"2001","unstructured":"Sanz-Altamira PM, O'Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, Saltz LB (2001) A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 12: 501\u2013504","journal-title":"Ann Oncol"},{"key":"BF6602208_CR29","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996b) Antitumor activity of 1\u2009M tegafur\u20130.4\u2009M 5-chloro-2,4-dihydroxypyridine\u20131\u2009M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602\u20132606","journal-title":"Cancer Res"},{"key":"BF6602208_CR30","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004\u20134009","journal-title":"Cancer Res"},{"key":"BF6602208_CR31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996a) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548\u2013557","journal-title":"Anticancer Drugs"},{"key":"BF6602208_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/oxfordjournals.annonc.a058597","volume":"4","author":"BG Taal","year":"1993","unstructured":"Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, Duez N, Sahmoud T (1993) Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 4: 607\u2013609","journal-title":"Ann Oncol"},{"key":"BF6602208_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/annonc\/mdf201","volume":"13","author":"J Ta\u00efeb","year":"2002","unstructured":"Ta\u00efeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M (2002) Optimization of 5-fluorouracil (5-FU)\/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13: 1192\u20131196","journal-title":"Ann Oncol"},{"key":"BF6602208_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000227373","volume":"51","author":"T Takada","year":"1994","unstructured":"Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T (1994) Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 51: 396\u2013400","journal-title":"Oncology"},{"key":"BF6602208_CR35","first-page":"748","volume":"78","author":"K Tatsumi","year":"1987","unstructured":"Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748\u2013755","journal-title":"Jpn J Cancer Res"},{"key":"BF6602208_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"N Tsavaris","year":"2004","unstructured":"Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22: 193\u2013198","journal-title":"Invest New Drugs"},{"key":"BF6602208_CR37","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/sj.bjc.6600781","volume":"88","author":"J Van den Brande","year":"2003","unstructured":"Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648\u2013653","journal-title":"Br J Cancer"},{"key":"BF6602208_CR38","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1200\/JCO.2000.18.14.2772","volume":"18","author":"CJ van Groeningen","year":"2000","unstructured":"van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18: 2772\u20132779","journal-title":"J Clin Oncol"},{"key":"BF6602208_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1023\/A:1008342315262","volume":"10","author":"JM van Riel","year":"1999","unstructured":"van Riel JM, van Groeningen CJ, Pinedo HM, Giaccone G (1999) Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 10: 157\u2013161","journal-title":"Ann Oncol"},{"key":"BF6602208_CR40","first-page":"939","volume":"16","author":"K Yee","year":"2002","unstructured":"Yee K, Sheppard BC, Domreis J, Blanke CD (2002) Cancers of the gallbladder and biliary ducts. Oncology (Huntingt) 16: 939\u2013957","journal-title":"Oncology (Huntingt)"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602208","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:13:13Z","timestamp":1684411993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,26]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["BF6602208"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602208","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,26]]}}}